{"entity":{"id":"folr1","kind":"target","name":"Folate receptor alpha","aka":[],"tldr":"Folate receptor alpha is a vitamin receptor that ovarian cancer cells carry in large numbers, used as the docking site for the ADC mirvetuximab.","summary":"FRα is overexpressed in high-grade serous ovarian cancer, endometrial cancer, and lung adenocarcinoma. Mirvetuximab soravtansine (Elahere) is approved in FRα-high platinum-resistant ovarian cancer (MIRASOL). Next-generation FRα ADCs with topoisomerase-I payloads (ZW191, luveltamab tazevibulin, rinatabart sesutecan) target lower-expressing tumours.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Folate_receptor_1","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Folate_receptor_1"}],"tags":["adc-target"],"related":["folr1-expression"],"cancers":["ovarian","endometrial","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pafolacianine","sofetabart-mipitecan","chiauranib","farletuzumab-exatecan"],"companies":["profoundbio"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07480954"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"symbol":"FOLR1","role":[],"sources":[],"specificity":"tumour-associated","distribution":"few-types","specificityNote":"Tumour-associated overexpression or amplification: 1 of 1 label readouts filed under it score protein level or gene copies (Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)), so the medicines rely on the tumour carrying more of it than normal tissue. HPA FOLR1: RNA tissue enriched (choroid plexus 2,861 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Ovarian cancer, Endometrial cancer, Lung cancer (all types)); Open Targets associates it with 1 specific cancer type at or above 0.5 (ovarian cancer). (Rule 3 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Folate receptor alpha expression (FRα-positive, PS2+ >= 75%) label threshold","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c424b5-6ccd-48ab-9e88-1986451120e2","note":"FRα-positive (PS2+ >= 75% on the Ventana FOLR1 assay)"},{"label":"Human Protein Atlas FOLR1 tissue","url":"https://www.proteinatlas.org/ENSG00000110195-FOLR1/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Human Protein Atlas FOLR1 pathology","url":"https://www.proteinatlas.org/ENSG00000110195-FOLR1/pathology","note":"patients per staining level per cancer type (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000110195 associations","url":"https://platform.opentargets.org/target/ENSG00000110195/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3791","ensembl":"ENSG00000110195","uniprot":"P15328","entrez":"2348","firstDescribed":1987,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Luhrs C.A. et al, Proc. Natl. Acad. Sci. U.S.A, 1987, \"Purified membrane and soluble folate binding proteins from cultured KB cells have similar amino acid compositions and molecular weights but differ in fatty acid acylation\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3476960/","biology":"GPI-anchored folate transporter; limited to apical surfaces in normal kidney, lung, and choroid plexus.","whereFound":["High-grade serous ovarian (~80% any expression)","Endometrial","NSCLC adenocarcinoma","TNBC (subset)"],"targetClass":"surface-antigen","prevalence":[{"cancerId":"ovarian","pct":"35-40","measure":"FRα-high (PS2+ in >=75% of cells)","source":"https://en.wikipedia.org/wiki/Folate_receptor_1","note":"MIRASOL eligibility; ~80% any expression"},{"cancerId":"endometrial","pct":"60-80","measure":"IHC, any expression","source":"https://en.wikipedia.org/wiki/Folate_receptor_1"},{"cancerId":"nsclc","pct":"70-80","measure":"Adenocarcinoma, any expression","source":"https://en.wikipedia.org/wiki/Folate_receptor_1"}]},"route":"/targets/folr1/","neighbours":{"biomarker":[{"id":"folr1-expression","kind":"biomarker","name":"Folate receptor alpha expression (FRα-positive, PS2+ >= 75%)","route":"/biomarkers/folr1-expression/"}],"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"high-grade-serous-ovarian-cancer","kind":"cancer","name":"High-grade serous ovarian cancer","route":"/cancers/high-grade-serous-ovarian-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"drug":[{"id":"chiauranib","kind":"drug","name":"Chiauranib","route":"/drugs/chiauranib/"},{"id":"farletuzumab-exatecan","kind":"drug","name":"Farletuzumab-exatecan","route":"/drugs/farletuzumab-exatecan/"},{"id":"luveltamab-tazevibulin","kind":"drug","name":"Luveltamab tazevibulin","route":"/drugs/luveltamab-tazevibulin/"},{"id":"mirvetuximab-soravtansine","kind":"drug","name":"Mirvetuximab soravtansine","route":"/drugs/mirvetuximab-soravtansine/"},{"id":"pafolacianine","kind":"drug","name":"Pafolacianine","route":"/drugs/pafolacianine/"},{"id":"rinatabart-sesutecan","kind":"drug","name":"Rinatabart sesutecan","route":"/drugs/rinatabart-sesutecan/"},{"id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","route":"/drugs/sofetabart-mipitecan/"}],"company":[{"id":"profoundbio","kind":"company","name":"ProfoundBio","route":"/companies/profoundbio/"},{"id":"sutro-biopharma","kind":"company","name":"Sutro Biopharma","route":"/companies/sutro-biopharma/"}],"trial":[{"id":"nct07480954","kind":"trial","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","route":"/trials/nct07480954/"},{"id":"mirasol","kind":"trial","name":"MIRASOL / GOG-3045","route":"/trials/mirasol/"},{"id":"rainfol-01","kind":"trial","name":"RAINFOL-01 (Rina-S)","route":"/trials/rainfol-01/"}],"term":[{"id":"hgsoc","kind":"term","name":"High-grade serous ovarian carcinoma (HGSOC)","route":"/terms/hgsoc/"}],"idea":[{"id":"idea-bio1-antigen-mapping-at-progression","kind":"idea","name":"Re-map the tumour's surface proteins before choosing the next antibody drug","route":"/ideas/idea-bio1-antigen-mapping-at-progression/"},{"id":"idea-fra-adc-sequencing-ovarian","kind":"idea","name":"Sequence folate-receptor ADCs by payload class","route":"/ideas/idea-fra-adc-sequencing-ovarian/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"person":[{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/"},{"id":"ursula-matulonis","kind":"person","name":"Ursula A. Matulonis","route":"/people/ursula-matulonis/"}],"target":[{"id":"muc16","kind":"target","name":"MUC16 (CA-125)","route":"/targets/muc16/"}],"institution":[{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","route":"/institutions/mayo-clinic-florida/"},{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","route":"/institutions/purdue-cancer-research/"},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","route":"/institutions/stephenson-oklahoma/"}],"pathway":[{"id":"mitotic-spindle-checkpoint","kind":"pathway","name":"Mitosis & the spindle assembly checkpoint","route":"/pathways/mitotic-spindle-checkpoint/"}]}}